Alendronate decreases BMD loss in prostate cancer

medwireNews: Weekly administration of oral biphosphonate alendronate could reduce loss of bone mineral density (BMD) in prostate cancer patients who start androgen-deprivation therapy (ADT), show study findings.

The 1-year trial, which was conducted across 30 urology sites in Canada, showed that the regimen not only prevented bone loss and increased bone mass, but it also decreased bone turnover.

Men initiating ADT are at risk for loss of BMD and osteoporotic fractures, yet the majority of men do not receive any treatment for this side effect, explain Laurence Klotz (Sunnybrook Health Sciences Centre, Toronto, Canada) and team. Calcium and vitamin D supplementation are recommended, although there is little support for this therapy in the setting of ADT.

The team conducted an intention-to-treat analysis of 167 patients initiating ADT therapy (leuprolide acetate 30 mg intramuscularly every 4 months), who were randomly allocated to receive either once-weekly oral alendronate 70 mg or placebo. All patients also took calcium 1 g and vitamin D 400 IU once daily.

As reported in European Urology, the mean spine BMD increased by 1.7% from baseline in the alendronate group, compared with a 1.9% decrease from baseline in the placebo group. Similarly, the mean total hip BMD increased by 0.7% in the alendronate group while it decreased by 1.6% in the placebo group.

The team also observed significantly greater improvements in markers for bone desorption as well as for bone formation and turnover.

The bone resorption marker, cross-linked N-telopeptide of type I collagen (Ntx), was decreased by a median of 3.5% in the alendronate group and increased by a median of 16.5% in the placebo group. Baseline urinary Ntx was also a significant predictor for loss of BMD.

Furthermore, bone-specific alkaline phosphatase, a marker of bone formation and turnover, was decreased by a median of 2.25% in the alendronate group and increased by a median of 3.12% in those who took placebo.

"Previous epidemiologic studies have suggested that high bone turnover is an independent risk factor for osteoporotic fractures," note Klotz and colleagues.

"Because loss of BMD in the ADT setting is associated with an increased fracture risk that is not mitigated by oral calcium and vitamin D supplementation, oral bisphosphonate therapy may have a role in men initiating androgen deprivation," concludes the team.

Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.

Sally Robertson

Written by

Sally Robertson

Sally has a Bachelor's Degree in Biomedical Sciences (B.Sc.). She is a specialist in reviewing and summarising the latest findings across all areas of medicine covered in major, high-impact, world-leading international medical journals, international press conferences and bulletins from governmental agencies and regulatory bodies. At News-Medical, Sally generates daily news features, life science articles and interview coverage.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robertson, Sally. (2018, August 23). Alendronate decreases BMD loss in prostate cancer. News-Medical. Retrieved on November 29, 2020 from

  • MLA

    Robertson, Sally. "Alendronate decreases BMD loss in prostate cancer". News-Medical. 29 November 2020. <>.

  • Chicago

    Robertson, Sally. "Alendronate decreases BMD loss in prostate cancer". News-Medical. (accessed November 29, 2020).

  • Harvard

    Robertson, Sally. 2018. Alendronate decreases BMD loss in prostate cancer. News-Medical, viewed 29 November 2020,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
New combination treatment for recurrent ovarian cancer shows positive outcomes